Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cannabis** is a non-single-entity botanical drug material obtained from Cannabis plants and containing a variable mixture of phytocannabinoids, terpenes, and other constituents. Its principal psychoactive constituent is typically delta-9-tetrahydrocannabinol, while cannabidiol and many other cannabinoids may also be present at highly variable concentrations. THC-mediated effects are principally produced through cannabinoid receptor 1 and cannabinoid receptor 2 signaling; therefore, the clinical pharmacology, efficacy, psychoactivity, and safety of cannabis depend substantially on chemotype, THC-to-CBD ratio, dose, route, and product preparation. Cannabis has been studied in defined inhaled, smoked, oral, and encapsulated preparations for pain, inflammatory bowel disease, cancer cachexia, respiratory symptoms, and inflammatory arthritis, but cannabis itself is not one standardized pharmaceutical chemical entity. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5812699/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabis.